Owkin
Summary
Drug discovery teams spend weeks pulling apart genomic datasets, literature, and clinical records just to get a directional answer on a single target — and by the time the answer arrives, the portfolio meeting has already happened. K Pro exists to collapse that cycle.
K Pro is an agentic AI scientist from Owkin that autonomously traverses multimodal biomedical data — genomics, spatial multi-omics, clinical trial records, competitive intelligence — and returns ranked, evidence-grounded answers to R&D questions. The vendor states it is trained on a proprietary multimodal patient data network and continuously refined by oncologists and biologists, which means its outputs are not generic literature summaries but claims tied to patient-level evidence. For target identification or patient stratification questions, that grounding matters. Where it breaks: teams that need to interrogate their own proprietary assay data or internal compound libraries will hit the edges of what K Pro's data network covers. The platform is not self-hosted, so data residency requirements that block cloud-based analysis force a different architecture entirely.
Bottom line: K Pro earns its place in an oncology pipeline team's weekly cadence for target ranking and patient population questions grounded in real-world data — but the moment your question depends on internal datasets you cannot move to a third-party cloud, you are designing a workaround before you start.
Pricing Plans
Subscription- Price
- Custom (contact vendor)
- Free Tier
- Initial signup includes free access to the beta version for a 6-month evaluation period; currently limited to a restricted number of users for the evaluation period, with a waitlist for others interested in joining
K Pro FREE
An agentic co-pilot designed for researchers to boost productivity, help generate hypotheses and explore multiomics; designed specifically to assist biologists and biomedical researchers in scientific writing, literature review, hypothesis testing, and data visualization
- Literature review and hypothesis testing
- Scientific writing assistance
- Data visualization
- Access to PubMed and biomedical databases
K Pro Light
Supports individual contributor exploration with one seat
- Single user seat
- Full K Pro platform access
- Basic multimodal data analysis
K Pro Standard
Supports team-based high-throughput exploration with high activity and 10 seats
- 10 user seats
- High-activity workflows
- Team collaboration features
K Pro Premium
Enterprise-wide decision-making with high activity and 100 seats
- 100 user seats
- Enterprise governance integration
- Dedicated account manager
- Custom agent development
View full pricing on owkin.com →
Pricing may have changed since last verified. Check the official site for current plans.
Community Performance Report Card
No community ratings yet. Be the first to rate this tool!
Community Benchmarks Community
Sign in to submit a benchmarkNo community benchmarks yet. Be the first to share a real-world data point.
Pros
Sign in to edit- Autonomous multi-step traversal of multimodal biomedical data — genomics, spatial biology, clinical records — so a target identification question that previously required a cross-functional team pulling data from separate systems returns as a ranked, evidence-backed report instead of a week-long sprint.
- Spatial multi-omics reporting built into the platform, which means tissue-context hypotheses that flat transcriptomic pipelines cannot express are answerable without standing up a separate analysis stack.
- Continuous refinement by a network of oncologists and biologists, so outputs carry domain validation rather than raw model outputs that a biology team must re-evaluate from scratch before trusting.
- API access available, so engineering teams can route K Pro's outputs into existing portfolio tracking or data warehouse pipelines rather than treating it as a standalone dashboard.
- A free-tier evaluation path, so a team can run real R&D questions against the platform before committing budget — avoiding the demo-looks-great, production-fails pattern that has burned previous tool adoptions.
Cons
Sign in to edit- Any question that depends on internal, unpublished compound data or proprietary assay results hits a hard wall: K Pro has no self-hosted option and no documented mechanism for ingesting datasets that cannot leave a team's infrastructure. Regulated pharma teams with data residency mandates are blocked entirely and evaluate federated or on-premise alternatives.
- The platform's strength is questions answerable from population-level biomedical evidence. Mechanistic hypotheses that require wet lab iteration loops beyond what Owkin's own infrastructure supports are not addressable through the tool alone — teams still need to maintain a separate experimental validation pipeline, which means K Pro becomes one input in a larger workflow rather than the workflow itself.
- Enterprise pricing is custom and opaque; teams cannot size budget against usage until they engage Owkin's sales process. For smaller biotech teams where procurement cycles are slow and headcount for vendor negotiation is limited, this blocks a fast build-vs-buy decision and pushes some teams toward academic or open-source tooling with predictable cost structures.
Community Reviews
Sign in to write a reviewNo reviews yet. Be the first to share your experience.
About
- Platforms
- Web-based SaaS; available on AWS Marketplace
- API Available
- Yes
- Self-Hosted
- No
- Last Updated
- 2026-06-09T17:54:55.158Z
Best For
Who it's for
- Pharmaceutical companies optimizing drug discovery pipelines
- Biotech firms evaluating therapeutic targets
- Academic research institutions analyzing complex genomic data
- Clinical development teams designing patient stratification strategies
- Investors and business development teams conducting competitive analysis
What it does well
- Target identification and ranking across oncology programs
- Clinical trial patient population optimization and biomarker discovery
- Competitive intelligence and drug landscape analysis
- Early portfolio decision-making and asset assessment
- Hypothesis generation and validation across multimodal biomedical data
Integrations
Discussion Community
Sign in to commentNo discussion yet. Sign in to start the conversation.
Compare Owkin
Spotted incorrect or missing data? Join our community of contributors.
Sign Up to ContributeCommunity Notes & Tips Community
Sign in to contributeBe the first to contribute. General notes, observations, gotchas, and tips from people who use this tool day-to-day.
Frequently Asked Questions
- Is Owkin free?
- Owkin is a paid tool (Custom (contact vendor)). A 180-day free trial is available.
- Is Owkin open source?
- No — Owkin is a closed-source tool. Source code is not publicly available.
- Does Owkin have an API?
- Yes. Owkin exposes a developer API. See the official documentation at https://owkin.com for details.
- When was Owkin released?
- Owkin was first released in 2025.
- What platforms does Owkin support?
- Owkin is available on: Web-based SaaS; available on AWS Marketplace.
Hours Saved & ROI Stories Community
Sign in to contributeBe the first to contribute. Concrete time/cost savings, with context. e.g. "Cut my code review backlog from 4h to 45m per week."
Curated lists that include this category
K Pro is Owkin’s decision-support agent for biopharma R&D, designed to answer the questions that currently take analysts days: which targets rank highest across an oncology program, which patient subpopulation a trial should be designed around, where a drug asset sits relative to the competitive landscape. The vendor describes it as agentic — it plans, retrieves, and synthesizes across multimodal biomedical data without requiring a human to script each step. The core workflow is query-driven: a researcher or portfolio lead poses a scientific or commercial question, K Pro autonomously executes across its connected data sources, and returns a structured, evidence-backed report. The platform includes a free-tier evaluation period and paid enterprise tiers scaled by usage and support depth.
The differentiating feature is the data substrate. K Pro is trained and validated on what Owkin describes as the world’s richest multimodal patient data network, explored through a wet lab infrastructure and validated by a global network of oncologists and biologists. A June 2026 collaboration with Sanofi for multi-year AI agent development signals that the platform has passed at least one large pharma’s production vetting bar. The spatial multi-omics reporting capability — bespoke reports powered by spatial biology data — goes further than standard transcriptomic analysis, addressing tissue-context questions that flat genomic datasets cannot answer.
K Pro fits cleanly when the question is answerable from population-level biomedical evidence: target ID, biomarker discovery, competitive drug landscape mapping, early portfolio triage. It breaks when the question depends on a team’s own unpublished compound data, proprietary in-house assay results, or any dataset that cannot leave the organization’s firewall — K Pro offers no self-hosted deployment option. Academic groups working primarily with public datasets and no cloud data restrictions are a reasonable fit; regulated pharma teams with strict data residency policies will need to resolve that constraint before any analysis reaches production.